LLY Sep 2024 680.000 put
| Previous Close | 6.45 |
| Open | 7.05 |
| Bid | 6.05 |
| Ask | 6.85 |
| Strike | 680.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 6.96 - 7.05 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 161 |
- Yahoo Finance Video
Jobs data, Alphabet's new CFO, HPE earnings: Three things
It's another busy day on Wall Street. Here are three of the top stories to watch in Wednesday's trading. The US added 152,000 private sector jobs in May, according to the latest ADP report. That's fewer than the 175,000 economists polled by Bloomberg were expecting. It's giving investors some hope that the Federal Reserve will cut rates sooner than some have been expecting. Alphabet (GOOGL, GOOG) announced Anat Ashkenazi, currently Executive Vice President and Chief Financial Officer at Eli Lilly (LLY), will be joining the company as its new CFO effective July 31. The tech giant announced last year that Ruth Porat would be stepping away from the role to become the company's President and Chief Investment Officer. Shares of Hewlett Packard Enterprise (HPE) are surging after reporting second quarter results that topped Street estimates and issuing better-than-expected Q3 and full-year guidance. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Stephanie Mikulich.
BloombergAlphabet Taps Eli Lilly Executive as New CFO Replacing Porat
(Bloomberg) -- Alphabet Inc. named Eli Lilly & Co. executive Anat Ashkenazi as its new chief financial officer, replacing Ruth Porat who announced last year she planned to step down. Most Read from BloombergModi Vows to Retain Power Even as Party Loses India MajorityBlackRock, Citadel Back Texas Stock Exchange in Challenge to NYSEModi’s Magic Is Fading Fast. Who’s Next for India?Short Sellers in Danger of Extinction After Crushing Stock GainsIndian Stocks Lead Gains in Asia as Modi Ally Pledges
Investor's Business DailyMadrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.
